MICROSPHERES FOR IMPROVED BIOAVAILABILITY

微球可提高生物利用度

• 批准号: 2396927
• 负责人: Edith Mathiowitz
• 金额: $ 30万
• 依托单位: BROWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-01 至 2001-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2396927
• 关键词: alpha benzopyrone; beta galactosidase; drug design /synthesis /production; gel electrophoresis; gene therapy; high performance liquid chromatography; insulin; laboratory rat; method development; microcapsule; paclitaxel; pharmacokinetics; plasmids; polymers; spectrometry

DESCRIPTION: The investigators propose to develop nanoparticulate biodegradable polymeric oral delivery systems for therapeutic agents representative of hydrophobic small molecules, proteins, and genes, and will study their uptake, as further described by their abstract: "Our project focuses on the development of nanoparticle-based, oral delivery systems, composed of biodegradable polymers, used to efficiently encapsulate and increase the bioavailability and uptake of three representative therapeutic agents from the most active fields of current research: small hydrophobic molecules (taxol), proteins (insulin) and genes. "Although much research has been performed with the first two systems, still there is a challenge to improve the oral bioavailability of these drugs. No product is commercially available on the market, particularly for the oral delivery of peptides and proteins. The last system is the most challenging one, since very little work has been done on oral delivery of genes. "Our hypothesis is that if we succeed in enhancing uptake of drug-loaded nanoparticles, then we may be able to enhance the bioavailability of each of the potential drug candidates. For taxol and insulin, we will target an increase in systemic bioavailability, while for plasmids the nature of he enhancement may be either local or systemic."

描述：调查人员建议开发纳米核心 治疗剂的可生物降解聚合物口服输送系统 代表疏水性小分子，蛋白质和基因的代表，将会 研究他们的吸收，如他们的摘要进一步描述： “我们的项目着重于基于纳米颗粒的口服交付的开发 由可生物降解的聚合物组成的系统，用于有效封装 并增加三名代表的生物利用度和吸收 当前研究最活跃领域的治疗剂：小 疏水分子（紫杉醇），蛋白质（胰岛素）和基因。 “尽管已经对前两个系统进行了许多研究，但仍在 改善这些药物的口服生物利用度面临挑战。 不 产品在市场上可商购，特别是对于口头 肽和蛋白质的递送。 最后一个系统是最具挑战性的 第一，由于对基因的口服递送很少工作。 “我们的假设是，如果我们成功增强了吸毒的吸收 纳米颗粒，然后我们可能能够增强每一个的生物利用度 潜在的候选药物。 对于紫杉醇和胰岛素，我们将针对 全身生物利用度增加，而对于质粒，他的性质 增强可能是本地的或全身的。”